N‐methyl‐D‐aspartate (NMDA) impairs myogenesis in C2C12 cells. Issue 3 (10th March 2017)

• Record Type: Journal Article
• Authors: Auh, Q‐SChick; Park, Kyung‐ran; Lee, Myeong‐ok; Hwang, Mi‐jin; Kang, Soo‐Kyung; Hong, Jung‐pyo; Yun, Hyung‐mun; Kim, Eun‐Cheol
• Is Part Of: Muscle & nerve. Volume 56:Issue 3(2017)
• Page Start: 510
• Page End: 518
• Publication Date: 2017-03-10
• Subjects: differentiation -- mTOR -- myalgic disorder -- myogenesis -- NMDA -- ROS; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.25511
• Languages: English
• ISSNs: 0148-639X

Abstract

ABSTRACT: Introduction: N‐methyl‐d‐aspartate (NMDA) is expressed in sensory neurons and plays important roles in peripheral pain mechanisms. The aim of this study was to examine the effects and molecular mechanisms of NMDA on C2C12 myoblast proliferation and differentiation. Methods: Cytotoxicity and differentiation were examined by the MTT assay, reverse transcription‐polymerase chain reaction, and immunofluorescence. Results: NMDA had no cytotoxicity (10–500 μM) and inhibited myoblastic differentiation of C2C12 cells, as assessed by F‐actin immunofluorescence and levels of mRNAs encoding myogenic markers such as myogenin and myosin heavy‐chain 2. It inhibited phosphorylation of mammalian target of rapamycin (mTOR) by inactivating mitogen‐activated protein kinases (MAPKs), including extracellular signal‐regulated kinase, c‐Jun N‐terminal kinase, and p38. It induced reactive oxygen species production. Furthermore, NMDA‐suppressed expression of F‐actin was reversed by adding the antioxidant N‐acetylcysteine. Conclusions: Collectively, these results indicate that NMDA impairs myogenesis or myogenic differentiation in C2C12 cells through the mTOR/MAPK signaling pathways and may lead to skeletal muscle degeneration. Muscle Nerve 56 : 510–518, 2017